Table 1. Clinical data and univariate analysis of overall survival.
| n (%) | Median OS, months (95% CI) | P value | |
|---|---|---|---|
| All patients | 100 (100) | 16 (13.9–18.1) | — |
| Age at diagnosis (years)a | 64 (30–89) | — | 0.26 |
| Gender: male | 67 (67) | — | 0.74 |
| Primary tumour location (n = 100) | 0.88 | ||
| Unknown | 24 (24) | 15 (11.9–18.1) | |
| Oesophagus | 4 (4) | 16 (0.0–38.5) | |
| Stomach | 11 (11) | 16 (3.6–28.4) | |
| Duodenum | 7 (7) | 14 (0.0–28.4) | |
| Pancreas | 23 (23) | 19 (12.3–25.7) | |
| Jejunum | 1 (1) | 11 (−) | |
| Colon | 10 (10) | 12 (3.2–20.8) | |
| Rectum | 16 (16) | 16 (3.5–28.5) | |
| Anal canal | 2 (2) | 18 (−) | |
| Otherb | 2 (2) | 16 (11.7–20.3) | |
| Clinical symptoms at diagnosis (n = 89) | |||
| Pain | 51 (57) | — | 0.96 |
| Weight loss | 36 (40) | — | 0.52 |
| Bowel disorders | 18 (20) | — | 0.41 |
| Icterus | 12 (13) | — | 0.16 |
| Mass syndrome | 5 (6) | — | 0.76 |
| ECOG-PS (n = 64) | 0.02 | ||
| <2 | 44 (69) | 18 (14.0–22.0) | |
| ≥2 | 20 (31) | 9 (7.0–11.0) | |
| Functioning tumours (n = 94) | 1, ACTH (1) | — | 0.23 |
| Stage (n = 100) | 0.02 | ||
| I–III (without metastasis) | 19 (19) | 25 (9.9–40.1) | |
| IV (with metastasis) | 81 (81) | 14 (11.5–16.5) | |
| Number of metastatic sites (n = 100) | 0.11 | ||
| 0 | 19 (19) | 25 (9.9–40.1) | |
| 1 | 42 (42) | 14 (12.4–15.6) | |
| 2 | 22 (22) | 12 (0.0–25.4) | |
| >2 | 17 (17) | 12 (8.5–15.5) | |
| Location of metastatic sites (n = 100) | |||
| Liver | 56 (56) | — | 0.11 |
| Lymph nodes | 50 (50) | — | 0.71 |
| Bone | 11 (11) | — | 0.99 |
| Lung | 11 (11) | — | 0.18 |
| Peritoneal | 6 (6) | — | 0.47 |
| Adrenal gland | 4 (4) | — | 0.64 |
| Brain | 4 (4) | — | 0.28 |
| Otherc | 7 (7) | — | 0.88 |
| Nuclear imaging | |||
| SRS uptake (n = 24) | 11 (48) | — | 0.11 |
| FDG-PET uptake (n = 46) | 42 (91) | — | 0.33 |
| Primary tumour resection (n = 100) | 0.004 | ||
| Yes | 28 (28) | 25 (14.1–35.9) | |
| No | 72 (72) | 13 (11.4–14.6) | |
| Metastasis resection (n = 100) | 0.32 | ||
| Yes | 11 (11) | 27 (8.5–45.5) | |
| No | 89 (89) | 15 (12.6–17.4) | |
Abbreviations: ACTH, Adrenocorticotropic hormone; CI, confidance interval; ECOG-PS, Eastern Cooperative Oncology Group Performance status; FDG-PET, fluorodeoxyglucose positron emission tomography; OS, overall survival; SRS, Somatostatin receptor scintigraphy; Notes: aMedian (range); bOther primary tumor sites: appendix (1), gallbladder (1); cOther locations of metastasis: kidney (1), muscle (1), cutaneous (2), pancreas (3), thyroid gland (1), breast (1), ovary (1).